What is Design Therapeutics Inc (DSGN) stock price today?

Design Therapeutics Inc (DSGN) currently trades at $13.41 per share. The stock has a market capitalization of $822.56M and a P/E ratio of —x.

Is DSGN stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Design Therapeutics Inc has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is 13.37.

What is Design Therapeutics Inc's revenue and earnings?

Design Therapeutics Inc has trailing twelve-month (TTM) revenue of $33000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-1.19.

Is Design Therapeutics Inc financially healthy?

Design Therapeutics Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of 13.37 places it in the safe zone.

DSGN

Design Therapeutics Inc

NASDAQ: DSGN · HEALTHCARE · BIOTECHNOLOGY

$13.41

+1.82% today

Updated 2026-05-05

Market cap

$822.56M

P/E ratio

—

P/S ratio

29,402.82x

EPS (TTM)

$-1.19

Dividend yield

—

52W range

$3 – $17

Volume

0.4M

Market cap

$822.56M

P/E ratio

—

P/S ratio

29,402.82x

EPS (TTM)

$-1.19

Dividend yield

—

52W range

$3 – $17

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

13.4

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →197 stocks currently score above 75

Price targets

Analyst target

$16.67

+24.31%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Altman Z 13.37 — safe zone

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-16.43M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$33000.00
Net income	$-58.62M	$-66.86M	$-49.59M	$-69.79M	$-17.64M
EPS	—	—	—	—	$-1.19
Free cash flow	$-52.23M	$-58.82M	$-43.45M	$-54.55M	$-16.43M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-31	SHAPIRO, DAVID	Buy	60,000	—
2026-03-31	SHAPIRO, DAVID	Buy	7,500	—
2026-01-02	STORGARD, CHRIS	Buy	250,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DSGN	$822.56M	24	4.3	3.0	5.0	8.0	—	Avoid
LLY	$862.01B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$546.90B	59	4.7	9.0	3.3	6.0	-40.34%	Buy
ABBV	$365.43B	63	4.0	8.0	4.0	5.0	-22.55%	Buy
UNH	$336.72B	54	5.3	5.5	7.3	4.8	+43.12%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+3.99%	Buy

Smart narrative

Design Therapeutics Inc trades at $13.41. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 13.37, it sits in the safe zone. TTM revenue stands at $33000.00.

Frequently asked questions

What is Design Therapeutics Inc's stock price?

Design Therapeutics Inc (DSGN) trades at $13.41.

Is Design Therapeutics Inc overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell).

What is the price target of Design Therapeutics Inc (DSGN)?

The analyst target price is $16.67, representing +24.3% upside from the current price of $13.41.

What is Design Therapeutics Inc's revenue?

TTM revenue is $33000.00.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

13.37 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.designtx.com

Quick metrics

P/S ratio29,402.82x

ROE-31.30%

Beta1.74

50D MA$11.50

200D MA$8.43

Shares out0.06B

Float0.03B

Short ratio—

Avg volume0.4M

Performance

1 week-15.07%

1 month+7.02%

3 months+34.10%

YTD+42.96%

1 year—

3 years—

5 years—

Compare

DSGN vs LLY →DSGN vs JNJ →DSGN vs ABBV →Stock screener →